Pitt-Hopkins Syndrome clinical trials at UCSF

1 research study open to eligible people

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
open to eligible people ages 3-17
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Pitt Hopkins Syndrome.
San Francisco, California and other locations

Last updated: August 3, 2023